Samsung Biologics Co Ltd Cash Flow Quality Index
Samsung Biologics Co Ltd cash flow quality index. Samsung Biologics Co Ltd (207940) has a Cash Flow Quality Index of 1.45x as of June 2026. Operating cash flow of ₩624.80 Billion exceeds net income of ₩430.65 Billion, indicating high earnings quality where cash backs reported profits. See Samsung Biologics Co Ltd (207940) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Samsung Biologics Co Ltd (2015–2025)
Cash flow quality index of Samsung Biologics Co Ltd from 2015 to 2025. Historical Cash Flow Quality Index for Samsung Biologics Co Ltd across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Samsung Biologics Co Ltd (207940) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Samsung Biologics Co Ltd Cash Flow Quality Index by Year (2015–2025)
Samsung Biologics Co Ltd cash flow quality index by year from 2015 to 2025. Year-by-year earnings quality comparison for Samsung Biologics Co Ltd. For the full cash flow conversion analysis, see 207940 cash flow conversion.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.26x | ₩2.25 Trillion | ₩1.78 Trillion | ▼ -17.8% |
| 2024 | 1.53x | ₩1.66 Trillion | ₩1.08 Trillion | ▼ -13.0% |
| 2023 | 1.76x | ₩1.67 Trillion | ₩945.92 Billion | ▲ +47.5% |
| 2022 | 1.19x | ₩953.05 Billion | ₩798.10 Billion | ▲ +3.4% |
| 2021 | 1.16x | ₩454.60 Billion | ₩393.59 Billion | ▲ +37.7% |
| 2020 | 0.84x | ₩202.09 Billion | ₩240.97 Billion | ▲ +1575.9% |
| 2019 | 0.05x | ₩10.15 Billion | ₩202.90 Billion | ▲ +134.0% |
| 2018 | -0.15x | ₩-33.02 Billion | ₩224.11 Billion | ▼ -6.5% |
| 2015 | -0.14x | ₩-265.51 Billion | ₩1.92 Trillion | — |